Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by Leerink Partnrs to Hold

Leerink Partnrs downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a strong-buy rating to a hold rating in a research note published on Friday, Zacks.com reports.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald restated an overweight rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. JPMorgan Chase & Co. restated a neutral rating and issued a $46.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. StockNews.com downgraded shares of Agios Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, August 5th. Royal Bank of Canada reissued an outperform rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. Finally, The Goldman Sachs Group lifted their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a neutral rating in a research report on Tuesday, June 4th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Hold and an average price target of $52.50.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $45.61 on Friday. Agios Pharmaceuticals has a 1-year low of $19.80 and a 1-year high of $53.28. The business has a 50 day moving average of $45.68 and a 200 day moving average of $39.68. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of -7.22 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The firm had revenue of $8.60 million for the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.51) earnings per share. As a group, sell-side analysts anticipate that Agios Pharmaceuticals will post -4.85 EPS for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.93% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC grew its position in shares of Agios Pharmaceuticals by 34.1% during the first quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock valued at $163,469,000 after purchasing an additional 1,423,000 shares in the last quarter. Marshall Wace LLP boosted its stake in Agios Pharmaceuticals by 307.8% during the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after buying an additional 855,739 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Agios Pharmaceuticals by 23.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock valued at $58,861,000 after buying an additional 388,381 shares in the last quarter. Frazier Life Sciences Management L.P. increased its stake in Agios Pharmaceuticals by 66.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock worth $37,600,000 after acquiring an additional 348,808 shares during the last quarter. Finally, Candriam S.C.A. purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $13,922,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.